T gonorrhea, or T-lymphoblastoma, has a variable time to relapse, depending on the patient’s condition, stage of disease and treatment. T-lymphoblastoma is highly malignant, has a poor prognosis, has a high recurrence rate, and is a highly aggressive tumor. The relapse rate of T-lymphoblastoma stages I and II is significantly lower than that of stages III and IV. The traditional salvage therapy for T-lymphoblastic lymphoma is a combination of chemotherapy with prednisone, vincristine, erythromycin, and levomucoidase through a modified BFM chemotherapy regimen and an increased dose of chemotherapy drugs, followed by autologous hematopoietic stem cell transplantation HSCT, to intensify chemotherapy to induce new disease-effective remission CR and reduce disease relapse rate. T-lymphoblastic lymphoma can effectively reduce the relapse rate after aggressive chemotherapy-based and radiotherapy-tuberculosis combination therapy, and should be followed up closely during treatment to pay attention to changes in the disease.